Navigation Links
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Date:2/2/2009

ellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. ABthrax blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells.

In contrast to the anthrax vaccine, the protection afforded by a single dose of ABthrax would be immediate following the rapid achievement of appropriate blood levels of ABthrax. In contrast to antibiotics, ABthrax acts against the deadly toxins produced by anthrax bacteria. It may also prevent and treat infections by antibiotic-resistant strains of anthrax. ABthrax was the first investigational agent against anthrax infection to be evaluated in a clinical study following the 2001 anthrax attacks in the United States. In 2003, ABthrax received a Fast Track Product designation from the FDA, as well as an Orphan Drug Designation for its use in the treatment of inhalation anthrax disease.

About the ABthrax Contract with the U.S. Government

In June 2006, the U.S. Government exercised its option to purchase ABthrax for the Strategic National Stockpile (Contract Number HHS010020050006C). HGS expects to receive $165 million in revenues from this award, with $150 million to come in the first half of 2009, following delivery of 20,000 doses of ABthrax, and the remainder to come upon FDA licensure of ABthrax. The purchase award was made by the HHS under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Strategic National Stockpile. Under the contract, HGS has manufactured and is now delivering 20,000 treatment courses of ABthrax to the Stockpile. Also under the contract, the Company plans to file a Biologi
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
3. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
4. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
5. 2008 Human Research Protection Award Recipients Announced
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
8. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon ... announced the completion of previously announced concurrent financing ... After fees and estimated offering expenses, Lexicon anticipates ... transactions.  The transactions consisted of: , ... stock, pursuant to a registration statement that has ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... 16, 2011 Get content from European Parliament ... The European Parliament is expected to pass ... medicines from entering the legal distribution chain in ... reached patients in the last years. The legislation ...
... SUNNYVALE, Calif., Feb. 16, 2011 ... today announced it will showcase its network scanning solutions ... hospitals and patients at the Annual HIMSS Conference & ... The adoption of network scanners has gained tremendous ...
Cached Medicine Technology:Fujitsu to Showcase New Document Imaging Technologies for Improved Information Sharing and Record Keeping at HIMSS 2011 2Fujitsu to Showcase New Document Imaging Technologies for Improved Information Sharing and Record Keeping at HIMSS 2011 3
(Date:11/28/2014)... (PRWEB) November 28, 2014 The ... techniques such as Dynamic Neuromuscular Stabilization, Extracorporeal Shock ... analysis. After moving to upgraded facilities in 2011, ... clinic. Now, owner Dr. Lev Kalika has launched ... injury prevention lab in the country. , The ...
(Date:11/28/2014)... The holiday season is fast approaching. As ... new collection of fashionable party dresses. What’s more, the company ... these brand new outfits; the special offer is valid until ... online supplier and it has received a lot of requests ... specially designed to flatter various body shapes; they are available ...
(Date:11/28/2014)... Brosix is always making changes to its infrastructure architecture ... efficient, effective, and secure experience. Most recently, the company ... ability to setup local servers for each country or ... around the globe. , 2. The ability to setup ... require millions of users in one network. , 3. ...
(Date:11/28/2014)... Orlando, FL (PRWEB) November 28, 2014 ... management solutions, announced its Release v5.1 which provides ... and enhanced workflow options. , “As we ... we continue to provide more functionality and improved ... states Robert Gambotz, CEO for Novatus. “With the ...
(Date:11/28/2014)... 2014 Dr. Diane Walder, one of ... treatment to her practice called Ultrashape that is designed to ... inches in just six weeks. Ultrashape has been praised by ... in results when compared to other types of external fat ... it,” said Dr. Walder. , According to Dr. Walder, ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3
... called NFATc1 tends to cause massive bone accumulation that ... investigator Gerald Crabtree and HHMI predoctoral fellow Monte Winslow ... formed and being broken down throughout life. Cells called ... it. ,‘Ideally, they are perfectly balanced,’ ...
... useful for the young doctors, to overcome the fatigue, who ... a little of sleep will lead to a substantial improvement ... doctors ability to care for their patients. ,In the ... researchers from the University of Chicago report that although average ...
... under-diagnosed till now was found to be more prevalent ... Explosive Disorder or Rage disorder is characterized by recurrent ... if left untreated may also lead to other mental ... attacks are out of proportion to the social stressors ...
... has revealed that men reaching fatherhood late in life may ... the genetic damage that increases with age//. ,US ... non-smoking men aged 22 to 80 and found a prevalence ... can be manifested as symptoms such as infertility, difficulty in ...
... The House of Representatives have passed a controversial bill ... would effectively take away //the power from local & ... foods and beverages that are likely to cause cancer, ... substances like mercury, like those required in California and ...
... for people with mild asthma, shallow breathing through the ... people to use a reliever inhaler very rarely//. ... are the most commonly used alternative for inhalers. A ... used by many people with asthma. ,Since ...
Cached Medicine News:Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Small Naps are Beneficial for Doctors to Overcome Fatigue 2Health News:Small Naps are Beneficial for Doctors to Overcome Fatigue 3Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 2Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 3Health News:Fathering Best Done In Early Years 2Health News:Association Asks People To Tell Their Senator To Vote against The "National Food Uniformity Act" 2
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
... exists as unbound or free testosterone. The ... with high affinity [1], while the remainder ... albumin-bound and free fractions may be biologically ... Measurement of the free or unbound fraction ...
... is a 32 kDa glycoprotein secreted by ... gland [1]. The structure of human TSH ... and placental gonadotropins, consisting of an a-subunit ... hormones and a unique beta-subunit, which confers ...
... Triiodothyronine (T3) is produced primarily by 5-monodeioination ... the thyroid gland, T3 production occurs at ... that for T4. Release of T3 from ... ~5-8 micrograms/day as compared to 80-100 micrograms/day ...
Medicine Products: